Acoustic neuroma screening
Jump to navigation
Jump to search
|
Acoustic neuroma Microchapters | |
|
Diagnosis | |
|---|---|
|
Treatment | |
|
Case Studies | |
|
Acoustic neuroma screening On the Web | |
|
American Roentgen Ray Society Images of Acoustic neuroma screening | |
|
Risk calculators and risk factors for Acoustic neuroma screening | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2] Mohsen Basiri M.D.
Overview
According to the U.S. Preventive Services Task Force (USPTF), screening for acoustic neuroma is not recommended. Evaluation for NF-2 should be done in individuals with an apparently sporadic vestibular schwannoma occurring before the age of 30, or a spinal tumor or meningioma occurring at less than 20 years of age.
Screening
- According to U.S. Preventive Services Task Force (USPTF), screening for acoustic neuroma is not recommended.
- Annual hearing screening with BAER (Brain stem auditory evoked response test), with referral to an audiologist for amplification, or speech therapy is recommended in patients with NF-2.
- Evaluation for NF-2 should be done in individuals with an apparently sporadic vestibular schwannoma occurring before the age of 30, or a spinal tumor or meningioma occurring at less than 20 years of age.[1][2]
References
- ↑ Evans DG, Ramsden RT, Gokhale C, Bowers N, Huson SM, Wallace A (2007). "Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma?". Clin Genet. 71 (4): 354–8. doi:10.1111/j.1399-0004.2007.00778.x. PMID 17470137.
- ↑ D. Gareth R. Evans (2009). "Neurofibromatosis type 2 (NF2): a clinical and molecular review". Orphanet journal of rare diseases. 4: 16. doi:10.1186/1750-1172-4-16. PMID 19545378. Unknown parameter
|month=ignored (help)